While the economy expands and contracts, the biopharma industry follows, and many life science companies are announcing both layoffs and expansions.

Bioduro-Sundia operates in the United States and China, with more than 2,000 employees and 10 facilities, providing contract research, development and manufacturing outsourcing services.

Nasal Swab, COVID

Panacell Biotech plans to initiate a program to investigate the use of natural killer (NK) immune cells, exosomes and brown adipose-derived stem cells to treat Long COVID.

FDA, stop sign

MaaT Pharma announced that the U.S. FDA has maintained the clinical hold on MaaT013, its candidate for patients with steroid-resistant acute graft-versus-host disease.

Spain has asked the European Medicines Agency (EMA) for permission to give more people a smaller dose of monkeypox vaccine, an approach known as “dose sparing” to distribute limited supplies as far as possible, the health ministry said.

Zantac

Shares in GSK, Sanofi and Haleon fell sharply on Thursday, following declines earlier this week, amid growing concerns about U.S. litigation over a heartburn drug that was pulled from the market in 2020 for containing a probable carcinogen.

Valneva

French vaccine developer Valneva on Thursday cut its full-year revenue outlook citing lower demand for its anti-COVID shot from European Union member states.

Walgreens Boots Alliance contributed to the opioid epidemic in San Francisco through its sale of prescription drugs in the city, a federal judge concluded on Wednesday.

CRISPR

The nonprofit biotech Cure Rare Disease (CRD) is headed to the clinic with a CRISPR therapeutic aimed at halting the progression of Duchenne muscular dystrophy in single-patient dosing.

Bristol-Myers Squibb

Within the next eight years, more than 3.5 million people in the United States are expected to be diagnosed with inflammatory bowel disease. With those rising numbers in mind, Bristol Myers Squibb is doubling down on treating the condition with a nearly $2 billion partnership with GentiBio to develop Treg therapies for patients with IBD.